A routine purchase at a Brooklyn bodega has exposed a disturbing trend in the booming, largely unregulated world of peptides: products marketed for miraculous health benefits are often nothing more than empty promises, potentially laced with unknown and harmful substances. An investigation by WIRED, which purchased injectable peptides from the Mr. Green bodega on a busy stretch of Bedford Avenue, found that the vials, despite claims of aiding everything from weight loss to injury recovery, contained no active peptide ingredients and posed an undisclosed risk to consumers.
The purchased peptides, acquired for $376.20 from a vendor named INDR Labs, included PT-141 (marketed for low libido), BPC-157 (for healing and muscle recovery), NAD+ (for cellular repair), and retatrutide (for weight loss). These substances are part of a broad class of amino acids that have surged in popularity, fueled by endorsements from public figures and the proliferation of telehealth services. However, many of these peptides have not undergone rigorous regulatory approval processes, and their sale for human consumption in the U.S. remains legally ambiguous, often operating under the guise of "research use only" to circumvent liability.
Following the purchase, WIRED sent the vials to Finnrick, an Austin-based startup that facilitates independent peptide testing. Consumers can submit samples to assess purity, identify contaminants, and verify the quantity of the advertised substance. Finnrick acts as an intermediary, connecting individuals with third-party laboratories. The results of this testing, delivered weeks later, delivered a stark reality: while the samples showed low levels of heavy metals and endotoxins, suggesting they were not immediately toxic, they failed to contain any of the advertised active peptide ingredients.
The Deception Uncovered: A Lab’s Verdict
The laboratory analysis performed for Finnrick revealed a critical deficiency: the vials labeled with specific peptide names, such as BPC-157, contained none of the promised compound. This indicates either a fundamental mislabeling of the products or a degradation of any initial correct ingredients due to improper storage. Peptides are notoriously sensitive to environmental factors, particularly temperature fluctuations, necessitating refrigeration to maintain their efficacy and integrity. The lack of proper handling and storage protocols in the supply chain is a significant concern.
Marco Krause, CEO of the laboratory that conducted the tests, emphasized the scope of their analysis: "What we offer is simply a label claim analysis. So you send us what you claim to think it is, and then we run it against a standard and verify whether or not it’s the right compound." This means the lab can confirm if the substance matches its purported identity, but cannot definitively identify what unknown substances might be present if the correct ingredient is absent.
A Booming, Yet Fraught, Industry
The surge in peptide popularity has been meteoric. Beyond celebrity endorsements, the narrative of peptides as potent performance enhancers and wellness boosters has permeated online communities and health discussions. Substances like GLP-1 agonists and insulin, which are FDA-approved pharmaceutical drugs, have paved the way for a broader acceptance of peptide-based therapies. However, many of the most talked-about peptides lack the same regulatory scrutiny, existing in a grey area of legality and scientific validation.
The "research use only" disclaimer, prominently displayed on signage at Mr. Green, is a common tactic employed by sellers to mitigate legal repercussions. Yet, as the WIRED investigation demonstrates, this label offers no assurance of product safety or efficacy, and in some cases, consumers are exposed to significant risks.
Raphaël Mazoyer, CEO of Finnrick, characterized the WIRED samples as "just duds." He noted an increase in such findings over the past three months, attributing this trend, in part, to the rise of "turnkey services" that facilitate the establishment of new peptide businesses with minimal expertise. "There are a whole bunch of labels popping up that have the same upstream vendor," Mazoyer explained, highlighting the potential for a single, unreliable supplier to contaminate multiple brands with substandard or counterfeit products.
Echoes of Deception: Independent Verification
WIRED’s findings are not isolated. Jeff Colhoun, founder of the research-peptide vendor directory Peptide Critic, conducted a similar investigation, purchasing INDR Labs peptides from Smoker’s World, another shop near Mr. Green. His samples of retatrutide and NAD+ were sent to Analytical Formulations, a Texas-based laboratory. The lab was unable to "positively identify" the substances, a result that, while not confirming the presence of harmful agents, strongly suggests contamination or degradation rendering the samples unidentifiable.
Colhoun echoed concerns about sellers bypassing "meaningful batch testing," leaving buyers vulnerable to the quality control failures of their suppliers. He has received similar reports from other vendors who encountered anomalous results during their own pre-sale product testing.
INDR Labs, the vendor in question, did not respond to WIRED’s request for comment. Following the inquiry, the company’s website began requiring login credentials, and access to its certificates of analysis, which previously claimed to be provided by Vanguard Laboratory, was restricted. A spokesperson for Vanguard Laboratory has denied issuing any such paperwork, according to a previous report by CBS News.
The Billion-Dollar Ecosystem and Regulatory Gaps
The peptide market is estimated to be a multi-billion dollar industry, with investors projecting its value to reach up to $3 billion. While the Food and Drug Administration (FDA) has begun to relax some regulations, and major telehealth platforms are gearing up to offer a wider array of peptides, a significant portion of the market operates through unregulated channels.
"The FDA needs to shut down these black markets," stated Fred Mills, a pharmacist and executive at Americans for Safe and Effective Medicines. Mills has actively engaged in discussions about the dangers of purchasing peptides from convenience stores and advises consumers to consult physicians before using such products.
The consequences of ingesting mislabeled or inert peptides can range from financial loss to serious health repercussions. In one tragic instance this year, a woman died after receiving a peptide injection from an unlicensed medical spa in the Bronx, underscoring the potential for severe harm when product integrity and professional oversight are compromised.
Darshan Kulkarni, an attorney specializing in pharmaceutical regulatory compliance, expressed alarm over the "legitimization" of products with unknown safety profiles. He contrasts the current peptide market with the stringent quality control measures in traditional pharmaceutical sales, such as visual inspections and barcoding, which are absent in the bodega-to-consumer model. "Someone selling a product at a bodega doesn’t know how to do that," Kulkarni observed.
Regulatory Response and Enforcement Challenges
An FDA spokesperson confirmed that the agency has issued warnings to companies marketing "research use only" products directly to consumers for human use, as well as to telehealth companies for making unsubstantiated claims about compounded GLP-1 products. The agency stated its commitment to taking appropriate action to protect public health. However, the FDA did not directly answer WIRED’s questions regarding whether it has investigated or taken enforcement action against brick-and-mortar retailers selling "research-only" peptides like those at Mr. Green.
While some enforcement actions have occurred, such as the six-year prison sentence for a man selling illegally imported, steroid-adulterated peptides, the overall regulatory landscape remains permissive. This allows for the continued easy acquisition of unapproved peptides through both online platforms and physical retail locations.
The perceived leniency in enforcement actions has been linked by some, like Kulkarni, to regulatory philosophies that prioritize innovation over stringent oversight, a stance that was prevalent during the Trump administration. This approach, he suggests, allows individuals to make their own product choices, even when those choices are based on potentially deceptive marketing.
As of early September, the prominent menu advertising peptides at Mr. Green had been removed from the window, though a smaller version remained near the counter, and the products were still available for purchase. This subtle shift suggests an awareness of scrutiny but no fundamental change in business practices.
The investigation serves as a stark reminder of the risks inherent in a rapidly expanding market where profit motives can overshadow consumer safety, leaving individuals vulnerable to the allure of quick fixes and unverified wellness claims. The empty promise of bodega-sold peptides highlights a critical need for enhanced regulatory oversight and consumer education in the burgeoning world of peptide therapeutics.
